$VNDA

12 Health Care Stocks Moving In Monday's Intraday Session

This article lists 12 healthcare stocks that experienced significant movement during Monday's intraday trading session. It highlights several gainers, including Arcellx (NASDAQ: ACLX) and Vanda Pharmaceuticals (NASDAQ: VNDA), and several decliners such as Gossamer Bio (NASDAQ: GOSS) and 20/20 Biolabs (NASDAQ: AIDX), along with their respective percentage changes and market caps.

Original reporting
Benzinga · Benzinga Insights, Benzinga Staff Writer
Published Feb 23, 2026, 5:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Feb 23, 2026, 5:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
12 Health Care Stocks Moving In Monday's Intraday Session — source image
Decision brief

The 30-second read

$VNDANeutralMed
01

Why it matters

Short-term trading opportunities exist based on intraday momentum; however, fundamental factors are not discussed.

02

Market read

The stocks mentioned are active in the healthcare sector with recent intraday volatility, providing potential trading opportunities for short-term traders.

03

What to watch

Broader market trends, upcoming earnings reports, and sector news could significantly influence stock movements beyond current data.

Timing: Immediate; intraday movements suggest short-term trading opportunities.

Background

The article reports on intraday movements of 12 healthcare stocks, highlighting both gainers and decliners.

Company-level read

Ticker impact

$VNDANeutralMedium confidence
Context

Moderate relevance; highlighted as a gainer but with less explicit sentiment data.

Expected impact

Potential slight upward movement of 1-2% if current trend persists.

Evidence & confidence

Limited sentiment data and moderate relevance imply cautious optimism; traders should monitor upcoming news for confirmation.

$GOSSBearishMedium confidence
Context

Low relevance; mentioned as a decliner with no specific sentiment data.

Expected impact

Possible further decline of 2-4% if negative momentum continues.

Evidence & confidence

Recent decline suggests bearish sentiment; risk of continued downward movement exists.

$AIDXBearishLow confidence
Context

Low relevance; minor mention as a decliner without detailed sentiment.

Expected impact

Potential for continued decline, but with low confidence due to limited data.

Evidence & confidence

Insufficient sentiment and technical data; traders should await further confirmation.

Market effects

Healthcare sector showing active trading, possibly indicating sector-wide volatility.

Limited; focus remains on specific stocks without broader regional implications.

Low; news pertains mainly to individual stocks within the US healthcare sector.

Counterpoint

The recent intraday gains may be temporary; overbought conditions could lead to reversals.

Key entities

  • Arcellx

    A biotechnology company focused on cell therapies.

  • Vanda Pharmaceuticals

    A biopharmaceutical company developing treatments for central nervous system disorders.

  • Gossamer Bio

    A biotechnology company developing therapies for various diseases.

  • 20/20 Biolabs

    A biotech firm engaged in developing novel therapeutics.

Related articles

$VNDAMedAI 8/10

VNDA: BYSANTI and NEREUS launches, plus pipeline catalysts, set the stage for major revenue growth

Vanda Pharmaceuticals Inc. [VNDA] launched two new drugs, NEREUS and BYSANTI. BYSANTI's launch and a switch strategy from Fanapt are expected to drive near-term revenue. The company aims for $750 million in psychiatry revenue by 2030, supported by phase III readouts and product diversification, according to its 12th Annual Cantor Fitzgerald Global Healthcare Conference.

$GOSSMedAI 8/10

Gossamer (GOSS) Announced Up to $250M of Financing, but Only $25M is Expected Upfront. Is the Runway Secure?

Gossamer Bio (GOSS) announced a private placement with up to $250M in gross proceeds, but only $25M is expected upfront. The remaining funds are contingent on regulatory milestones for seralutinib, a drug for pulmonary arterial hypertension. The company ended June with $57M in cash, expecting the initial $25M to improve near-term liquidity but not fully secure its runway.

$VNDAMedAI 8/10

Vanda receives EU orphan designation for imsidolimab GPP treatment

Vanda Pharmaceuticals (VNDA) received EU orphan designation for imsidolimab, a potential treatment for generalized pustular psoriasis, following a positive opinion from the EMA. The designation, the first for a GPP treatment in the EU, may provide regulatory and market benefits. The company's Biologics License Application for imsidolimab is under FDA review with a target action date of December 12, 2026.

$VNDAMed

Vanda Wins First EU Orphan Designation For Imsidolimab In Generalized Pustular Psoriasis; Stock Up

Vanda Pharmaceuticals (VNDA) received EU Orphan Drug Designation for Imsidolimab to treat generalized pustular psoriasis. The designation, granted by the European Commission, follows a positive opinion from the EMA. Imsidolimab targets the IL-36 signaling pathway. VNDA's stock rose 6.06% in pre-market trading. The FDA is reviewing the drug's BLA with a target action date of December 12, 2026.